scPharmaceuticals Inc. (NASDAQ:SCPH) Holdings Raised by King Luther Capital Management Corp

King Luther Capital Management Corp boosted its stake in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 51.8% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 2,205,140 shares of the company’s stock after purchasing an additional 752,005 shares during the quarter. King Luther Capital Management Corp owned 0.06% of scPharmaceuticals worth $9,592,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of SCPH. AIGH Capital Management LLC raised its holdings in shares of scPharmaceuticals by 40.8% during the fourth quarter. AIGH Capital Management LLC now owns 3,106,795 shares of the company’s stock valued at $19,480,000 after acquiring an additional 899,786 shares during the period. IPG Investment Advisors LLC acquired a new stake in shares of scPharmaceuticals during the 4th quarter valued at about $75,000. Rubric Capital Management LP grew its stake in shares of scPharmaceuticals by 29.0% in the 4th quarter. Rubric Capital Management LP now owns 3,500,000 shares of the company’s stock valued at $21,945,000 after buying an additional 786,713 shares in the last quarter. Thomasville National Bank increased its holdings in scPharmaceuticals by 11.5% in the first quarter. Thomasville National Bank now owns 36,800 shares of the company’s stock worth $185,000 after buying an additional 3,800 shares during the last quarter. Finally, Perkins Capital Management Inc. bought a new position in scPharmaceuticals during the first quarter valued at approximately $53,000. 89.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a research report on Monday, August 19th.

scPharmaceuticals Trading Down 1.5 %

scPharmaceuticals stock opened at $5.18 on Friday. scPharmaceuticals Inc. has a one year low of $3.24 and a one year high of $7.37. The company’s fifty day moving average price is $4.96 and its two-hundred day moving average price is $4.70. The company has a debt-to-equity ratio of 4.32, a current ratio of 4.84 and a quick ratio of 3.66. The company has a market capitalization of $259.16 million, a price-to-earnings ratio of -3.50 and a beta of 0.13.

scPharmaceuticals (NASDAQ:SCPH) last released its earnings results on Wednesday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.44). scPharmaceuticals had a negative return on equity of 201.84% and a negative net margin of 252.18%. The firm had revenue of $8.05 million for the quarter, compared to analyst estimates of $8.04 million. On average, analysts forecast that scPharmaceuticals Inc. will post -1.34 earnings per share for the current fiscal year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.